HIV testing as the bridge between awareness and acceptance of PrEP among MSM

Similar documents
Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?

PrEP for Women: HIV Prevention in Family Planning Settings

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

PrEP efficacy the evidence

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

Using anti-hiv drugs for prevention

Drug development in relation to PrEP and the PROUD study

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Pre-exposure Prophylaxis for HIV Prevention

The HIV Prevention Pill: The State of PrEP Science and Implementation

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

IAPAC Summit Daily And Intermittent PrEP

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Multiple choice questions: ANSWERS

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

HIV PREVENTION. ETHICAL CONSIDERATIONS IN DEVELOPING AN EVIDENCE BASE FOR PrEP IN PREGNANT WOMEN

Biomedical Prevention Update Thomas C. Quinn, M.D.

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know

PrEP in the Real World: Clinical Case Studies

WHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

Overview of ARV-based prevention trials

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

HIV Pre-Exposure Prophylaxis (PrEP)

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

PrEP Dosing Strategies

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

Government of Canada Federal AIDS Initiative Milestones

Pre-exposure Prophylaxis (PrEP)

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

CROI 2015: HIV Prevention Updates

CATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM

Pre-exposure prophylaxis (PrEP)

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations

Combination prevention: Public health and human rights imperatives

Guidelines for PrEP in PWID

Unmet Oral Health Needs of Persons Living With HIV/AIDS in the United States

ART and Prevention: What do we know?

HIV Clinical Update- HIV prevention

STIs in the Indian Country

Understanding the Results of VOICE

PrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014

emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd

Oral pre-exposure prophylaxis (PrEP)

HIV Prevention Strategies HIV Pre-exposure prophylaxis

Pre-exposure Prophylaxis and Primary Care

Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies

Pre-Exposure Prophylaxis PrEP where are we now? Marie Laga Institute of Tropical Medicine

BLT mice in HIV prophylaxis

HHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 01.

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

Sexual Health reproduction in reference to treatment as/for prevention

Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013

2020 Vision: making England s HIV prevention response the best in the world

The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients

Biomedical Prevention in HIV

The role of Integrase Inhibitors during HIV prevention

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

Strategic use of antiretroviral drugs to prevent HIV transmission

HIV Pre- Exposure Prophylaxis

PrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine

Malaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh

UK community perspective on PrEP and PROUD. Simon Collins

during conception, pregnancy and lactation at 2 U.S. medical centers

TasP - Individual versus Public Health Benefit versus Both.

Los Angeles County PATH: PrEP and TLC+ for HIV Prevention. PATH Community Advisory Board Member Application

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Strategies for Using Pre-Exposure Prophylaxis (PrEP) to Lower HIV Incidence in Select Populations

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

PEP and PrEP: AWAAC 2014

Can we treat our way out of the HIV epidemic?

Shebeen Attendees Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa

Ending the Epidemic: What Clinicians Need to Know

Cutting Edge and Interventions of Promote PrEP Adherence. Martin Hoenigl, MD; University of California San Diego

Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health

10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital

Transcription:

PA_3 #08 HIV testing as the bridge between awareness and acceptance of PrEP among MSM Tsz Ho Kwan, BSc, MIET PhD Candidate in Public Health 1 June 2017

Content Background HIV epidemiology in Hong Kong MSM community PrEP Current situation of PrEP in Hong Kong Objective Methods Results Conclusions 2

Background 43% (3579/8410) of all HIV cases in Hong Kong were infected through homosexual/bisexual transmission (1984-2016) Men who have sex with men (MSM) accounted for 61% newly diagnosed cases in 2016 Chan KCW. Press conference on local HIV/AIDS situation in 2016. [Presentation] Centre for Health Protection. 28th February 2017. 3

Background Pre-exposure prophylaxis (PrEP) Daily pill containing two HIV drugs (TDF/FTC) To prevent HIV infection Efficacy in MSM: 86% [PROUD] / 99%[iPrEx] World Health Organization (WHO) recommendation (2016): Oral pre-exposure prophylaxis (PrEP) containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches (strong recommendation, high-quality evidence) Anderson PL, et al. Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. McCormack S, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016; 387(10013):53-60. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach - Second edition. 4 Geneva: World Health Organization; 2016.

Background PrEP is currently unavailable in Hong Kong 1.12% (5/444) MSM had taken PrEP before [unpublished] 5

Background In order to facilitate PrEP promotion and implementation, understanding factors associated with awareness and acceptance is crucial 6

Objective To assess the role of different variables, particularly HIV testing, in affecting awareness and acceptance of PrEP among Hong Kong MSM 7

Methods An online self-administered survey was conducted for 2 months Variables were dichotomised and categorised into 5 groups Demographics Considerations when seeking partners Networking patterns Sexual behaviours PrEP-related factors 8

Methods PrEP-related factors Awareness Acceptance Assuming the degree of recognition, efficacy, price, and safety are identical, which PrEP regimen do you prefer the most? Daily Time-driven Event-driven Injectable Would not consider taking PrEP Service model 9

Methods φ coefficient was measured for each variable pair T-test was used to assess directional correlation Correlations with p<0.01 were regarded significant 10

Methods Network approach Node: Factor Edge: Significant correlation Variable A Variable B Variable C Variable E Variable F Variable D 11

Methods Factors with direct significant association with awareness or acceptance of PrEP were included in the network as a node Correlations between all these factors were also added to the network Variable A Variable B Variable C Acceptance of PrEP Awareness of PrEP Variable D 12

Methods Betweenness centrality of a node was assessed to identify important variables in the factor network The normalised number of all-pairs shortest paths passing through a node 1 4 3 2 5 13

Results A total of 444 MSM without known HIV infection were recruited Aug Sep 2016 113 variables established 804 significant links (13% of all possible links [aka density]) 14

Results Demographics Networking patterns Considerations when seeking partners Sexual behaviours PrEP-related factors Negative association Positive association Legend 15

Results Negative association Positive association 0.00 Betweenness centrality Legend 0.39 0.50 0.30 0.22 0.07 0.07 16

Conclusions Engagement in HIV testing plays an important role in one s acceptance of PrEP 17

Conclusions Sexual health-conscious MSM accepted PrEP, but their risk levels and the needs of PrEP are not known 18

Conclusions Effective dissemination of information relating to sexual health depends on the understanding of the pattern of MSM s networking channels There is a need to introduce PrEP through specific platforms to raise the community s awareness 19

Conclusions Integrating pre-prep screening (including, for example, risk assessment) and referral in community-based testing services could be an important strategy to achieve HIV prevention 20

Acknowledgements Funding agency Research Grants Council of Hong Kong (RGC Ref. No.: 14103315) Technical support Li Ka Shing Institute of Health Sciences 21

PA_3 #08 The end Thank you for your attention